WO2001034805A3 - Human vanilloid receptor gene - Google Patents

Human vanilloid receptor gene Download PDF

Info

Publication number
WO2001034805A3
WO2001034805A3 PCT/US2000/031077 US0031077W WO0134805A3 WO 2001034805 A3 WO2001034805 A3 WO 2001034805A3 US 0031077 W US0031077 W US 0031077W WO 0134805 A3 WO0134805 A3 WO 0134805A3
Authority
WO
WIPO (PCT)
Prior art keywords
vanilloid receptor
human vanilloid
receptor gene
polynucleotides
human
Prior art date
Application number
PCT/US2000/031077
Other languages
French (fr)
Other versions
WO2001034805A2 (en
Inventor
Jeffrey N Masters
Melissa H Vos
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to JP2001537501A priority Critical patent/JP2003513669A/en
Priority to CA002359955A priority patent/CA2359955A1/en
Priority to CA002428827A priority patent/CA2428827A1/en
Priority to EP00982103A priority patent/EP1144628A3/en
Publication of WO2001034805A2 publication Critical patent/WO2001034805A2/en
Publication of WO2001034805A3 publication Critical patent/WO2001034805A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides an isolated or purified polynucleotide that encodes human vanilloid receptor. Isoforms of human vanilloid receptor are also disclosed. The invention also provides methods of making recombinant human vanilloid receptor using the polynucleotides and host cells transformed with the polynucleotides.
PCT/US2000/031077 1999-11-12 2000-11-10 Human vanilloid receptor gene WO2001034805A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001537501A JP2003513669A (en) 1999-11-12 2000-11-10 Human vanilloid receptor gene
CA002359955A CA2359955A1 (en) 1999-11-12 2000-11-10 Human vanilloid receptor gene
CA002428827A CA2428827A1 (en) 1999-11-12 2000-11-10 Human vanilloid receptor gene
EP00982103A EP1144628A3 (en) 1999-11-12 2000-11-10 Human vanilloid receptor gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43899799A 1999-11-12 1999-11-12
US09/438,997 1999-11-12

Publications (2)

Publication Number Publication Date
WO2001034805A2 WO2001034805A2 (en) 2001-05-17
WO2001034805A3 true WO2001034805A3 (en) 2001-11-22

Family

ID=23742867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031077 WO2001034805A2 (en) 1999-11-12 2000-11-10 Human vanilloid receptor gene

Country Status (4)

Country Link
EP (1) EP1144628A3 (en)
JP (1) JP2003513669A (en)
CA (2) CA2359955A1 (en)
WO (1) WO2001034805A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1009804B1 (en) 1997-08-20 2003-10-29 The Regents of the University of California Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
GB9826359D0 (en) * 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
US20020072101A1 (en) * 2000-01-21 2002-06-13 Gaughan Glen T. Novel human nucleic acid molecules and polypeptides encoding cation channels
US6455278B1 (en) * 2000-02-08 2002-09-24 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding human vanilloid receptor VR3
HUP0300489A3 (en) * 2000-02-25 2006-06-28 Daiichi Seiyaku Co Novel protein and gene encoding the same
DE10013296A1 (en) * 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma New nucleic acid encoding the non-selective cation channel OTRPC4, useful for treating osmolality-associated disorders, e.g. diabetes comprises the modulation of activity
JP3501775B2 (en) * 2000-05-31 2004-03-02 ファイザー株式会社 Human vanilloid receptor-like protein
GB0026114D0 (en) * 2000-10-25 2000-12-13 Smithkline Beecham Plc New use
DE10257421A1 (en) * 2002-12-09 2004-07-08 Grünenthal GmbH Regulatory elements in the 5 'region of the VR1 gene
WO2006005472A1 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vanilloid receptor 1 (vr1)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037675A1 (en) * 1998-01-22 1999-07-29 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptors
EP0943683A1 (en) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037675A1 (en) * 1998-01-22 1999-07-29 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptors
EP0943683A1 (en) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CATERINA M J ET AL: "THE CAPSAICIN RECEPTOR: A HEAT-ACTIVATED ION CHANNEL IN THE PAIN PATHWAY", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 389, 23 October 1997 (1997-10-23), pages 816 - 824, XP002075020, ISSN: 0028-0836 *
DATABASE EMBL 21 June 1999 (1999-06-21), MUZNY D.M. ET AL.: "Homo sapiens chromosome 12 clone RP1-7G5, WORKING DRAFT SEQUENCE, 12 unordered pieces", XP002167767 *
WARDLE K.A. ET AL.: "Pharmacological characterization of the vanilloid recptor in the rat isolated vas deferens", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 48, 1996, pages 285 - 291, XP002919258 *

Also Published As

Publication number Publication date
WO2001034805A2 (en) 2001-05-17
EP1144628A2 (en) 2001-10-17
EP1144628A3 (en) 2002-02-27
CA2428827A1 (en) 2001-05-17
CA2359955A1 (en) 2001-05-17
JP2003513669A (en) 2003-04-15

Similar Documents

Publication Publication Date Title
EP1009814A4 (en) Human receptor tyrosine kinase, kdr
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO2001023592A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
WO1999054461A3 (en) Human nucleic acid sequences of endometrium tumour tissue
WO1999055858A3 (en) Human nucleic acid sequences obtained from pancreas tumor tissue
WO2001034805A3 (en) Human vanilloid receptor gene
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
WO2000054651A3 (en) Human tumor necrosis factor receptor-like genes
WO1999054460A3 (en) Human nucleic acid sequences of normal bladder tissue
WO1999046374A3 (en) Human nucleic acid sequences from prostate tumour tissue
WO2001016334A3 (en) Human hydrolytic enzymes
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
DK1196442T3 (en) VGF polypeptides and methods for the treatment of VGF-related disorders
WO1999047655A3 (en) Human nucleic acid fragments with heightened expression in normal breast tissue
WO1998033937A3 (en) GENOMIC SEQUENCE OF THE HUMAN ν-OPIOID RECEPTOR GENE AND THE VARIANTS, POLYMORPHISMS AND MUTATIONS THEREOF
WO2000063415A8 (en) Dna encoding the human vanilloid receptor vr1
WO1998030692A3 (en) Human endosulfine gene
AU2676801A (en) Xylosyltransferase and isoforms thereof
WO1994017189A3 (en) Protein kinases
WO1999046375A3 (en) Human nucleic acid sequences from prostate tissue
WO1998059041A3 (en) Disease related nucleotide kinases
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: CA

Ref document number: 2359955

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000982103

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 537501

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007196

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2000982103

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2428827

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000982103

Country of ref document: EP